Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Overview of Immutep Ltd
Immutep Ltd is a globally active biotechnology company committed to advancing immunotherapy for both cancer and autoimmune diseases. Leveraging its expertise in immuno-oncology and innovative LAG-3 technology, the company has positioned itself as a specialized entity in personalized bio-therapeutic products. With dual listings on the Australian Stock Exchange and Nasdaq, Immutep demonstrates a robust international presence and a solid foundation in research and development.
Core Technology and Therapeutic Approach
The hallmark of Immutep’s approach is its focus on the LAG-3 immune control mechanism, a critical regulator of the T cell immune response. By modulating this pathway, Immutep aims to enhance the body’s natural ability to fight cancer and potentially address autoimmune conditions. This technology underpins the company’s strategic pipeline and sets a high standard for clinical precision and targeted therapy development.
Product Pipeline and Clinical Development
Immutep’s product portfolio is centered around its most advanced candidate, IMP321, which functions as a T cell immunostimulatory factor. This therapy is designed for integration into cancer chemoimmunotherapy protocols and has achieved significant clinical milestones in early phase trials. In addition to IMP321, the company is developing IMP701, a blocking anti-LAG-3 antibody candidate in early clinical evaluation, and CVac, a personalized immunocellular strategy under investigation for epithelial cancers. These development efforts illustrate a diverse and forward-looking approach that integrates both innovation and strategic collaboration.
Global Operations and Strategic Collaborations
Operating primarily from Australia, Immutep extends its influence across global markets, supported by strong regulatory compliance and research proficiency. Strategic partnerships with large pharmaceutical firms reinforce its pipeline development, enabling access to advanced clinical platforms and shared expertise. The company’s qualification for significant research tax incentives in both Europe and Australia underscores its commitment to high-caliber R&D and validates the commercial and scientific merits of its initiatives.
Industry Position and Business Model
Within the competitive landscape of biotechnology, Immutep differentiates itself by combining deep scientific expertise with a focused therapeutic strategy. Its business model hinges on collaborative partnerships, clinical innovation, and a targeted approach to harnessing LAG-3 mediated immune modulation. Investors and industry observers appreciate the rigorous clinical frameworks employed by the company, which underpin its potential to offer novel therapeutic modalities in the area of cancer treatment and beyond.
Research and Development Excellence
Immutep’s strategic emphasis on research and development is reflected in its participation in international R&D incentive programs. These initiatives not only provide substantial financial support for its clinical trials but also affirm the company’s adherence to high industry standards and scientific integrity. This relentless focus on innovation is at the core of Immutep’s operational ethos, ensuring that its immunotherapeutic solutions are developed in a rigorous and transparent environment.
Conclusion
In summary, Immutep Ltd stands as a key player in the biotechnology industry, with a specific focus on immunotherapy modalities for cancer and autoimmune diseases. Its reliance on advanced LAG-3 technology, comprehensive product pipeline, and robust global partnerships collectively fortify its standing in the competitive landscape. The company’s commitment to R&D excellence and transparent clinical strategies provides a rich source of insight for those seeking to understand a pioneering approach in modern biotechnology.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful completion of patient recruitment for the Phase II TACTI-002 study, targeting non-small cell lung cancer (NSCLC) and head & neck squamous cell carcinoma (HNSCC). With 185 patients enrolled across all study parts, recruitment was completed under 12 months, surpassing expectations. Interim data from Part C was presented at the SITC Annual Meeting 2021, with further results anticipated in early 2022. This milestone reflects Immutep's commitment to advancing immunotherapy research in challenging pandemic conditions.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of a new patent from the Chinese Patent Office for its immunotherapy candidate, eftilagimod alpha (efti or IMP321). The patent protects combined therapeutic preparations involving efti and anti-PD-1 or anti-PD-L1 antibodies, expiring on January 8, 2036. This follows similar patents granted in Europe and the U.S. between 2018 and 2021. The patent is exclusively licensed to EOC Pharma, which will pay milestone payments and royalties as efti progresses through trials in China.
Immutep Limited (NASDAQ: IMMP) presented promising data at the SITC Annual Meeting 2021, highlighting significant Overall Survival (OS) improvements in patient subgroups from its AIPAC trial. Key findings indicate a median OS of 22.3 months for patients under 65 and 32.5 months for those with low monocyte counts. The Phase II TACTI-002 study revealed a 29.7% Overall Response Rate (ORR) in second-line head and neck cancer patients. The company’s candidate, efti, continues to show potential for improving quality of life and long-term outcomes in cancer treatment.
Immutep Limited has reported promising results from the TACTI-002 trial, noting an Objective Response Rate (ORR) of 29.7% in patients with second-line head and neck squamous cell carcinoma (HNSCC). This study included 37 patients, with 5 achieving complete responses. Additionally, Immutep will recruit 154 first-line HNSCC patients for the TACTI-003 study to assess ORR as the primary endpoint. Detailed data from the AIPAC trial will be presented in an investor webcast on November 17, 2021.
Immutep Limited announced promising final overall survival (OS) data from its Phase IIb AIPAC trial, indicating a median OS of 20.4 months for patients treated with efti and paclitaxel, compared to 17.5 months with placebo. The trial demonstrated significant survival benefits in predefined patient subgroups: +7.5 months for patients <65 years, +19.6 months for those with low monocytes, and +4.2 months for luminal B cancers. A Phase III trial is planned, focusing on these results, which underline the efficacy of efti as an immunotherapy in metastatic breast cancer.
Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent in China for its lead product candidate, eftilagimod alpha (efti). This patent, numbered ZL 201610221687, protects the use of efti combined with chemotherapy for cancer treatment, expiring on October 3, 2028. This addition to Immutep's patent portfolio follows similar grants in Europe, Japan, and the US. The patent is exclusively licensed to EOC Pharma, which will pay milestone fees and royalties as efti progresses in clinical development.
Immutep Limited (NASDAQ: IMMP) has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for eftilagimod alpha (efti), particularly the planned Phase III trial in metastatic breast cancer (MBC). This follows encouraging results from the ongoing Phase IIb AIPAC trial. The EMA's support allows Immutep to proceed with the trial design, which will involve multiple countries. Additional regulatory discussions are ongoing with the US FDA.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced key developments in its clinical trials and financial situation for the quarter ended 30 September 2021. The company received approvals for the Phase IIb TACTI-003 trial and successfully enrolled the first patient in the INSIGHT-003 study. Preparations for a new Phase III trial (AIPAC-003) in metastatic breast cancer are ongoing. Financially, Immutep reported cash receipts of $56k and a cash balance of $106.39 million, enhancing its financial position with cash reach extending to December 2023.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced that data from its Phase II TACTI-002 trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, held in Washington, US, from November 10-14, 2021. Additionally, results from the Phase IIb AIPAC trial will be shared as a late breaker poster presentation. The poster abstracts will be published on November 9, 2021, followed by new data on November 12, 2021. TACTI-002 evaluates efti with pembrolizumab in treating head and neck cancer patients.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced a significant cash boost of €2,126,617 (~ A$3,430,952) from the French Government via its Crédit d’Impôt Recherche scheme. This R&D tax incentive benefits the company’s European research efforts conducted during the 2020 calendar year. Additionally, Immutep received a A$1,155,055 rebate from the Australian Federal Government for similar activities. The funds will aid in the global clinical development of eftilagimod alpha and the preclinical development of IMP761.
FAQ
What is the current stock price of Immutep (IMMP)?
What is the market cap of Immutep (IMMP)?
What is the core focus of Immutep Ltd?
How does Immutep utilize LAG-3 technology in its treatments?
What are the key products in Immutep’s development pipeline?
In what ways does Immutep engage in global operations?
How do Immutep’s strategic partnerships influence its business model?
What role do research tax incentives play in Immutep’s operations?
How does Immutep maintain its expertise and trustworthiness in the biotech industry?
